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Introduction: Depressive disorders are among the main causes of disability due to disease. In 
spite of recent progress in the pharmacotherapy of depression, there is still a high nonresponse 
rate of ∼30% to the first antidepressant treatment. Furthermore, the latency of several weeks 
until sufficient clinical improvement and the risk of side effects remain unresolved problems. 
Therefore, there is still further need for the development of new antidepressants. In the last years 
a variety of melatonin receptor agonists have been synthesized and evaluated for the treatment of 
sleep disorders. Animal studies suggested that agomelatine (S-20098), a synthetic melatonergic 
MT1 and MT2 receptor agonist with serotonin receptor antagonistic properties, may have addi-
tional activating properties and may represent a new approach in the treatment of depression.
Aims: Clinical trials that have demonstrated efficacy and safety of agomelatine for the treatment 
of depression are reviewed.
Evidence review: In clinical trials, including phase III studies, superior efficacy compared to 
placebo and good efficacy compared to standard antidepressants was shown for agomelatine 
for the acute treatment of major depression. In all studies published so far agomelatine was 
safe and the overall tolerability profile was superior to selective serotonin reuptake inhibitors 
or selective serotonin and norepinephrine reuptake inhibitors.
Place in therapy: Agomelatine may represent a novel perspective in the treatment of acute 
depression. The improvement of sleep disturbances, the tolerability in terms of sexual side 
effects, and the lack of withdrawal symptoms after abrupt discontinuation of treatment may 
represent important clinical benefits compared to established antidepressants.
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Core evidence place in therapy summary for agomelatine in major depression
Outcome measure Evidence Implications
Patient-oriented evidence
reduction of depressive  
symptoms
Clear Agomelatine more effective than placebo and as effective 
as paroxetine or venlafaxine
improvement of sleep Clear Earlier and better improvement on subjective getting to sleep 
and on subjective quality of sleep compared to venlafaxine
Disease-oriented evidence
Symptom relief in terms of  
HAM-D reduction
Clear Agomelatine more effective than placebo and as effective 
as paroxetine or venlafaxine
response to treatment Clear Agomelatine as effective as paroxetine and venlafaxine
remission after treatment Clear Agomelatine as effective as paroxetine and venlafaxine
Economic evidence
Cost effectiveness
No  
evidence
So far, no information about costs of the drug on European 
market. Studies required to validate assumption that 
better tolerability profile will translate into improved cost 
effectiveness
HAM-D, Hamilton rating scale for depression.Core Evidence 2009:3 172
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Scope, aims, and objectives
Melatonin secretion underlies strict circadian rhythms1 and 
is regulated via the cAMP signal transduction cascade.2 
Several studies have reported beneficial effects of melatonin 
for the treatment of sleep disorders. However, the therapeu-
tic use of melatonin, which is offered as a supplement in 
the US, is restricted by its low bioavailability. Therefore, 
several melatonin agonists have been developed in recent 
years and examined in clinical trials for the treatment of 
insomnia (for a current review of melatonin receptor agonist 
development, see Turek and colleagues3). To date, agomela-
tine (S-20098; Valdoxan®, Servier), a synthetic melatonergic 
MT1 and MT2 receptor agonist,4 is the best characterized 
melatonin receptor agonist in terms of preclinical studies. 
In contrast to melatonin, agomelatine also possesses sero-
tonin (5-HT2C) receptor antagonistic properties5 within the 
central nervous system (CNS). Several preclinical studies 
indicated that agomelatine has activating6 and antidepressant 
effects, which are comparable to the antidepressant efficacy 
of established antidepressants. Therefore, agomelatine may 
represent a new approach for the treatment of depression. The 
efficacy and tolerability of agomelatine in the acute treatment 
of depressive disorders has been evaluated in several con-
trolled clinical trials. In the following article the evidence for 
agomelatine’s antidepressant efficacy will be reviewed and its 
place in the acute treatment of depression will be discussed.
Methods
The medical literature was reviewed for appropriate articles 
relating to agomelatine on PubMed (http://www.ncbi.nlm.
nih. gov) using the search terms “agomelatine OR S-20098.” 
The search was updated on September 1, 2008. One hundred 
and sixteen articles were found, of which 11 were written in 
languages other than English and were therefore excluded. 
Within those 105 publications, 12 reports from clinical 
trials and 24 review articles have been identified. Out of the 
reports from clinical trials, 10 are included and also cited in 
this review (Table 1). Additionally, congress proceedings 
focussing on the effects of agomelatine in the treatment of 
depression were also included where appropriate.
So far no pharamacoeconomic studies of agomelatine 
have been published. The results of the included clinical trials 
are reviewed, focussing on clinical efficacy, safety, and toler-
ability of agomelatine in the treatment of major depression.
Disease overview
Depressive disorders are among the main causes of disability 
due to disease and the World Health Organization (WHO) 
estimates that they will be the second most important cause of 
disability by the year 2020.7 Chronic depressive episodes are 
common and are associated with greater illness burden and 
socioeconomic disadvantage.8 Throughout Europe, 23% of 
years of healthy life are lost and approximately one-third of 
all burden of disease is caused by neuropsychiatric diseases.9 
The 1-year prevalence of depression in Europe is around 
5%.10 The life time prevalence of depression varies widely 
from 3% in Japan to 16.9% in the US, with most countries 
in the range between 8%–12%.11 Despite intensive biologi-
cally oriented psychiatric research over the last decades, the 
etiology of depressive disorders is not yet fully understood, 
although a multifactorial genesis is supposed. Besides psy-
chologic and social factors, biologic variables apparently 
play a major role that lead to a disturbed CNS homeostasis. 
The so-called catecholamine- and serotonin-deficiency 
hypothesis,12 which postulates a deficiency of monoamines 
(norepinephrine and serotonin) within the synaptic cleft, 
plays a major role in the understanding of the pathophysiol-
ogy of depression.
Current therapy options
The treatment of depressive disorders consists of a complex 
multimodal therapy that is determined by the current state 
of the illness. The treatment of depression includes pharma-
cotherapy, psychotherapy, and sociotherapy. Whereas phar-
macotherapy is not always mandatory for less severe forms 
of depression, severe depression usually requires pharmaco-
therapy or electroconvulsive therapy. In addition, a variety 
Table 1 Evidence base included in the review
Category Number of records
  Full papers Abstracts
initial search 116
  records excluded 11
  records included 105
Total records included 10 4
Level 1 clinical evidence
(systematic review, meta analysis) 0 0
Level 2 clinical evidence (rCT) 5 1
Level  3 clinical evidence
  Trials other than rCT 2
  Case reports
Other outcome than depression 3 3
Economic evidence 0  
For definitions of levels of evidence, see Core Evidence website (http://dovepress.
com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:3 173
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of other biologic interventions, such as sleep deprivation and 
bright light therapy, may be of use in certain patient sub-
groups. The discovery of tricyclic antidepressants (TCAs) was 
a milestone in the treatment of depression. However, in spite 
of the undoubted effectiveness of TCAs it soon became appar-
ent that their anticholinergic and antihistaminergic side effects 
may cause problems. As a consequence, new antidepressants 
were developed with a more selective mode of action, which 
mainly aimed at avoiding these side effects. Currently, tri- and 
tetracyclic antidepressants with predominant serotonergic, 
noradrenergic, or mixed serotonergic/noradrenergic action 
are available. In addition, selective and reversible inhibitors 
of the monoamine oxidase A, an irreversible monoamine 
oxidase B inhibitor, nonselective and irreversible inhibitors of 
the monoamine oxidase, selective serotonin reuptake inhibi-
tors (SSRI), selective norepinephrine reuptake inhibitors, and 
antidepressants with a dual mode of action such as selective 
serotonin and norepinephrine reuptake inhibitors (SNRI), and 
noradrenergic and specific serotonergic antidepressants acting 
via blockade of alfa2 and 5-HT2 receptors, are all available.13–17 
The most recently investigated mechanism of action is the 
agonism at melatonergic MT1 and MT2 receptors and selec-
tive antagonism at serotonergic 5-HT2C receptors represented 
by the antidepressant agomelatine,5 which is currently under 
review by authorities in Europe.
Unmet needs
Although newer antidepressants are better tolerated and cause 
fewer side effects, their specific side-effect profile has to be 
taken into account during the treatment of depression. In addi-
tion, the latency of several weeks until the onset of sufficient 
therapeutic effects remains a serious and clinically relevant 
problem. This principle holds true for each antidepressant 
and each class of antidepressant mechanisms. A further 
general problem in pharmacotherapy of depression is the 
possible nonresponse to the first antidepressant treatment.18–20 
Approximately 30% of depressed patients do not show suf-
ficient improvement after the first course of an adequate 
antidepressant treatment and a further 20% discontinue due 
to tolerability problems.21 Adequacy of treatment includes the 
use of a treatment with proven efficacy during a time interval 
of at least 4–6 weeks in a sufficient therapeutic dose range 
including reliable patient adherence to therapy.19,22,23 Half 
of patients who do not respond adequately to a first course 
also fail to respond to a second antidepressant treatment 
trial. If several antidepressant treatment trials have been 
inefficacious, even lower response rates after switching to 
another drug may be observed.24
Clinical evidence for agomelatine 
in the treatment of major depression
Melatonin secretion underlies strict circadian rhythms1 and is 
regulated via the cAMP signal transduction cascade.2 A variety 
of animal studies and clinical trials in depressed patients sug-
gest that agomelatine, a synthetic melatonergic MT1 and MT2 
receptor agonist4 with 5-HT2C receptor antagonistic properties5 
within the CNS, has activating and antidepressant effects.6
In several animal models of depression agomelatine has 
been shown to possess antidepressant effects that were com-
parable to those of established antidepressants. In contrast 
to melatonin the beneficial effects of agomelatine did not 
depend on the time of administration, indicating that besides 
the chronobiotic, other properties may contribute to its anti-
depressant-like activity.25 Furthermore, agomelatine has been 
shown to have chronobiotic activity similar to melatonin in 
animal models of disturbed circadian rhythms.26,27
Clinical efficacy assessment
Clinical trials focus on symptomatic relief measured by 
specific scales, such as the Hamilton Depression Score 
(Hamilton Depression Rating Scale, HAM-D),28 and define 
response and remission in relation to these scores. The 
traditional definition of response to antidepressant therapy 
includes a 50% improvement in symptoms (usually 50% 
reduction of the baseline score). Remission is defined as the 
absence of depressive symptoms and a full return to premor-
bid levels of functioning. In most randomized controlled trials 
an absolute rating scale threshold is defined as remission 
(eg, HAM-D score  7). Goals of clinical management can 
be divided into acute, intermediate, and long-term goals. 
The ultimate goal of acute treatment is to achieve remission, 
meaning not only being asymptomatic (in the sense of not 
meeting the criteria for diagnosis of the disorder and having 
no or only minimal residual symptoms) but also showing 
improvement in psychosocial and occupational functioning. 
The intermediate goal is further stabilization and prevention 
of a relapse, elimination of subsyndromal symptoms, and 
restoration of the prior level of functioning. The long-term 
goal is full recovery,29 to prevent further episodes, maintain 
functioning, and ensure a satisfactory quality of life.30–32
Clinical efficacy of agomelatine  
in phase ii and iii trials
Symptomatic relief
The clinical efficacy of agomelatine in the treatment of 
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randomized, double-blind, placebo-controlled trial.33 In this 
study three different doses of agomelatine were compared 
with an active comparator. Seven hundred and eleven patients 
aged between 18 and 65 years, who were suffering from 
major depressive disorder (n = 698) or bipolar II depres-
sion (n = 13) according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV),34 
with a minimum severity score of 22 in the 17 item HAM-D 
(HAM-D17)35 were treated with agomelatine, paroxetine, or 
placebo. After an obligatory 1-week placebo run-in period, 
patients were randomized to receive agomelatine 1, 5, or 
25 mg once daily in the evening, paroxetine 20 mg/day in 
the morning, or placebo during the 8-week study period. 
After exclusion of placebo responders during the run-in 
period (defined as HAM-D17 improvement 20%) the 
mean HAM-D17 score at baseline was 27.4 and the mean 
Montgomery-Asberg Depression Rating Scale (MADRS)36 
score was 31.5, indicating a moderately to severely depressed 
study population. One-third of the patients had a depressive 
episode of severe intensity, defined as HAM-D17 score  25. 
The treatment groups showed no significant differences in 
either demographic or clinical variables.
The intent-to-treat analysis using the last observation 
carried forward method in patients who had received at least 
one post-randomization treatment and had a baseline and at 
least one postbaseline rating, showed a statistically significant 
superiority in the mean scores of all agomelatine-treated 
patients taken together in comparison to the placebo-treated 
group. Subsequent distinct analyses of the three agomelatine 
treatment groups, however, showed clear effectiveness 
only in the patient group that received 25 mg/day, whereas 
agomelatine 1 and 5 mg/day did not differ from placebo. 
The time to first response was significantly shorter in the 
agomelatine 25 mg/day group in comparison to placebo. In 
contrast to paroxetine, which first showed significant advan-
tages after 4 weeks, agomelatine 25 mg/day was significantly 
superior to placebo already after 2 weeks of treatment.
The clinical efficacy of agomelatine in major depression 
has been confirmed in further randomized, double-blind, 
placebo-controlled studies. In the study published by Kennedy 
and Emsley,37 212 outpatients were treated with agomelatine 
25 mg/day, with the possibility of increasing the dose to 
50 mg/day in case of insufficient improvement after 2 weeks 
of treatment.38 After a 6-week treatment period, agomelatine 
was significantly more effective in comparison with placebo. 
Patients treated with agomelatine had a significantly 
lower HAM-D score (P = 0.0017) at endpoint (14.1 ± 7.7) 
compared with patients receiving placebo (16.5 ± 7.4). 
Furthermore, there was a significant improvement of severity 
of disease measured with the Clinical Global Impression 
Scale (CGI-S) score with agomelatine compared with placebo 
(3.2 ± 1.3 versus 3.6 ± 1.3; P = 0.0017). Thirty-six (34%) 
patients in the agomelatine and 38 (37%) patients in the 
placebo group failed to improve after 2 weeks of treatment. 
Therefore, in the agomelatine group the dosage was increased 
to 50 mg/day, while placebo-treated patients continued to 
receive placebo. Also in this subgroup of increased agomela-
tine-treated patients, significant improvements in HAM-D 
score were observed at study endpoint. The HAM-D score 
decreased in the agomelatine-treated patients from 26.1 ± 2.6 
at baseline to 17.5 ± 7.4 at week 6, compared with a decrease 
from 26.7 ± 2.8 to 20.4 ± 6.0 in the placebo group.
In a further double-blind, parallel-group, flexible-dosing 
study,39 an interactive voice response system was used as a 
novel blinding method. Two hundred and thirty-eight patients 
with moderate-to-severe major depression were treated with 
agomelatine over 6 weeks. In case of insufficient improve-
ment at week 2, dose adjustment from agomelatine 25 to 
50 mg/day was possible. In terms of HAM-D final scores 
agomelatine was significantly more efficacious than placebo 
with an agomelatine-placebo difference of 3.44 (P = 0.001). 
Furthermore, in terms of severity of disease measured 
with CGI-S, agomelatine significantly improved CGI and 
decreased CGI-severity compared with placebo.
Further evidence for the efficacy of agomelatine came 
from a double-blind, randomized study with the main goal 
of investigating the effects of agomelatine on sleep improve-
ment.40 In this flexible-dose study, 332 outpatients suffering 
from major depression were treated with agomelatine 
25–50 mg/day or venlafaxine 75–150 mg/day. After 6 weeks 
of treatment the antidepressant efficacy of agomelatine in 
terms of CGI global improvement was comparable to that 
of venlafaxine.
response and remission
Analysis of response and remission rates during agomelatine 
treatment suggested that agomelatine exerts high efficacy in 
the treatment of depressive disorders. In the first random-
ized, double-blind, placebo-controlled trial of agomelatine33 
response, defined by an improvement of 50% in the HAM-D 
score, was achieved significantly more often in the agomela-
tine 25 mg/day (61.5%) and agomelatine 1 mg/day (62.5%) 
group in comparison with placebo (46.3%) as shown by pair-
wise comparison. In contrast, neither agomelatine 5 mg/day 
(51.4%) nor paroxetine (56.3%) was significantly superior 
to placebo. In this study remission defined by a HAM-D17 Core Evidence 2009:3 175
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score at endpoint below 7 was achieved significantly more 
often with agomelatine 25 mg/day (30.4%) and paroxetine 
(25.7%) than with placebo (15.4%).
Significant efficacy of agomelatine was also found in a 
randomized, double-blind, multicenter study of agomelatine 
versus paroxetine published with the main goal of inves-
tigating discontinuation symptoms in sustained remitted 
patients.41 During the first part of the study 335 outpatients 
with major depression (DSM-IV) with a mean MADRS score 
of 23 were treated after a drug-free run-in period with either 
agomelatine 25 mg/day or paroxetine 20 mg/day once daily 
for 12 weeks. One hundred and ninety-two patients achieved 
sustained remission, defined as an MADRS score  12 
at weeks 8, 10, and 12. The rate of sustained remitters was 
52.7% in the agomelatine and 61.9% in the paroxetine group. 
At the time of the second randomization, at entry into the 
discontinuation period, there were no statistically significant 
differences between the two groups.
Furthermore, in a recently published study by Kennedy 
et al,42 investigating sexual dysfunction in 276 depressed 
patients during antidepressant therapy with agomelatine 
50 mg/day or the SNRI venlafaxine extended release 
150 mg/day over a period of 12 weeks, comparable high 
remission rates (defined as an MADRS score  12) of 73% 
in the agomelatine and 66.9% in the venlafaxine group have 
been observed.
Although it has to be considered that unequal definitions 
of remission, different dosages, and different treatment 
intervals might account for differences in the observed 
remission rates, these study results indicate that agomelatine 
exerts antidepressant efficacy that leads not only to treatment 
response but also to a rate of sustained remission similar to 
that of established antidepressants.
Response rates were also significantly higher with 
agomelatine 25–50 mg/day (54.3% and 49.1%) than with 
placebo (35.5% and 34.2%) in two randomized, double-blind, 
flexible-dosing studies.37,39
Specific subgroups of depressed patients
The antidepressant efficacy of agomelatine has also been 
proven in the subgroup of severely depressed patients, 
defined by the generally accepted criterion of a baseline 
HAM-D17 score  25.
In the study by Loo et al33 an analysis of the subgroup 
of severely depressed patients (n = 586) revealed that 
patients treated with agomelatine 25 mg/day (n = 120) but 
not those receiving the lower doses differed significantly 
from placebo-treated patients (n = 114) in terms of HAM-D 
final scores (13.14 ± 8.4 versus 16.1 ± 9.1). In contrast, the 
active comparator paroxetine was not significantly superior 
to placebo in this study population (HAM-D final score 
14.1 ± 8.4).
Similarly, in the study published by Kennedy and 
Emsley,37 76 severely depressed patients were treated with 
agomelatine and 75 severely depressed patients were treated 
with placebo. Treatment with agomelatine resulted in a 
significantly lower HAM-D score at endpoint compared with 
placebo (14.4 ± 7.9 versus 17.3 ± 7.2; P = 0.024). Moreover, 
in the study population with severe depression, the difference 
in mean HAM-D score at endpoint between agomelatine and 
placebo exceeded the difference in the full study population 
(2.72 ± 1.19 versus 2.30 ± 1.02) indicating high efficacy of 
agomelatine in severely depressed patients.
In addition, first results from open-label studies indicated 
that agomelatine may not only be effective in the treatment 
of major depression, but also in the treatment of bipolar and 
seasonal affective disorder (SAD).
Agomelatine 25 mg/day as an adjunctive therapy to 
lithium (n = 14) or valpromide (n = 7) significantly improved 
depressive symptoms in bipolar I patients after 6 weeks of 
treatment,43 and agomelatine 25 mg/day yielded a signifi-
cant decrease in depressive symptoms measured with the 
Structured Interview Guide for the HAM-D SAD-version, 
CGI-S, and CGI-I in 37 patients suffering from SAD.44
Depression-associated sleep disturbances
In view of its pharmacologic profile agomelatine is likely to 
possess sleep-wake cycle regulating properties. In several 
animal models of disturbed circadian rhythms agomelatine 
has been shown to have chronobiotic activity similar to 
melatonin. These results are also of particular interest for 
the treatment of affective disorders since a disorganization 
of circadian rhythms is suggested to play an important role 
in the pathophysiology of major depression.45,46
The influence of agomelatine 50 mg/day on circadian 
rhythms was investigated in a double-blind, placebo-controlled, 
crossover study in healthy, older, adult men.47 At the end of 
the 15-day active treatment period, significant 2-hour phase 
advances in the 24-hour profiles of body temperature and 
cortisol levels were found. Similar trends were seen in thyroid 
stimulating hormone secretion. Polysomnographic investiga-
tions, however, showed no effects of agomelatine on normal 
sleep patterns suggesting that agomelatine facilitates the 
realignment of overt circadian rhythms in older adults.
In addition, in patients with major depression treated with 
agomelatine 25 mg, polysomnography shows regulation of Core Evidence 2009:3 176
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sleep-wake rhythms increasing the duration of slow wave 
sleep and normalizing its distribution through the night.48 
After 6 weeks of treatment sleep efficiency, time awake after 
sleep onset, and the total amount of slow wave sleep increased. 
In contrast agomelatine did not change rapid eye movement 
(REM) latency, amount of REM, or REM density.49
In addition, in a dose-finding study,33,50 somatic complaints 
and symptoms related to sleep disturbances decreased 
substantially throughout the study, further indicating that 
agomelatine has beneficial effects in the treatment of 
depression-related sleep disturbances.
In a double-blind, randomized study in 332 outpatients 
suffering from major depression, the effects of agomelatine 
25–50 mg/day and venlafaxine 75–150 mg/day on subjec-
tive sleep quality were compared. In contrast to venlafaxine, 
agomelatine showed an earlier and better improvement on 
subjective getting to sleep and on subjective quality of sleep 
as well as a better improvement of daytime sleepiness.40 
These results indicate that agomelatine may contribute to a 
normalization of disrupted circadian rhythms in depression 
via phase-shifting properties without direct sedation and 
therefore not disturbing the normal day-sleep rhythm.
Safety and tolerability
In all clinical trials published to date, agomelatine has a better 
safety and tolerability profile than established antidepres-
sants, including the investigated SSRIs and SNRIs.
In a first dose-finding pilot study in 28 patients no 
modifications of cardiovascular parameters or biologic 
abnormalities were seen after a 4-8 week treatment period 
with agomelatine 5 or 100 mg/day.33,50 Slightly more adverse 
events and severe treatment-related adverse events were seen 
in the 100 mg/day group.
In the above mentioned large, double-blind study by 
the same authors,33 56.5% of 711 patients reported at least 
one adverse event that emerged or worsened during the 
study such as headache, abdominal pain, nausea, diarrhea, 
somnolence, or anxiety. No significant difference between 
agomelatine and placebo was seen, whereas during parox-
etine treatment significantly more gastrointestinal adverse 
events, predominantly nausea, were seen than with placebo. 
Again no clinically relevant changes in vital signs, weight, 
or cardiovascular parameters, including electrocardiogram 
recordings, were seen with agomelatine. In a further pla-
cebo-controlled trial, adverse events more common in the 
agomelatine group compared with placebo were dizziness 
(9.3% versus 4.8%), nasopharingitis (6.5% versus 3.8%), 
and influenza (6.5% versus 2.9%).37
Remarkably,  although  agomelatine  ameliorates 
sleep-related complaints, no sedation has been reported during 
the daytime. Impairment of sexual function has been reported 
for antidepressants and represents an important cause of 
noncompliance.51 Therefore, the effects of agomelatine on 
sexual function were studied in a specific trial.42,52 Using 
a sexual function questionnaire, sexual dysfunction was 
compared between agomelatine and venlafaxine extended 
release.42 Treatment-emergent sexual dysfunction was 
significantly less prevalent in the agomelatine group. Desire, 
arousal, and orgasm scores and the total sexual dysfunc-
tion score was significantly greater in venlafaxine-treated 
patients. In order to distinguish between medication-induced 
sexual side effects and sexual symptoms associated with 
depression an additional analysis of sexually active patients 
who achieved remission (defined by a decrease of at least 
50% in the MADRS score compared to baseline and a total 
MADRS score  12 after 10 weeks of treatment) was carried 
out. In this analysis 7.3% of agomelatine-treated patients 
compared with 15.7% of venlafaxine recipients reported 
a deterioration of sexual function. While men more often 
reported a decline in drive and desire, women more often 
reported deterioration of orgasm.
Discontinuation symptoms were investigated in a 
randomized, placebo-controlled, double-blind study41 in 
88 patients with major depression who were sustained 
responders after agomelatine 25 mg/day treatment lasting 
12 weeks (the control group received paroxetine 20 mg/day). 
Sixty-one patients continued agomelatine whereas 27 were 
abruptly switched to placebo. After 1 week of treatment 
interruption no statistically significant difference in the 
number of discontinuation symptoms between patients 
treated with agomelatine and those receiving placebo was 
observed. In contrast to these findings, 43 patients dis-
continuing the SSRI paroxetine experienced significantly 
more discontinuation symptoms, such as insomnia, muscle 
aches, dizziness, and nausea, than another 61 patients who 
continued treatment with the SSRI. After 2 weeks of treat-
ment interruption the agomelatine group continued to show 
similar results to the placebo group and there were no sig-
nificant differences between the paroxetine and the placebo 
group. No significant differences in the rates of relapse or 
partial relapse were registered in either of the active treatment 
groups or in the placebo group during the observation period 
of 2 weeks, which was relatively short for the estimation of 
the relapse risk. Nevertheless, patients who discontinued from 
paroxetine experienced a significantly greater worsening in 
CGI and MADRS scores in comparison to patients continuing Core Evidence 2009:3 177
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the medication, which might be attributed to the emergent 
withdrawal symptoms in the paroxetine discontinuation 
group. Patients discontinuing agomelatine showed the same 
low severity of depressive symptoms as patients continuing 
the medication. During the discontinuation period no serious 
adverse events were recorded.
This study showed agomelatine was not associated with 
discontinuation symptoms during the observation period 
of 2 weeks. Because the half-life of agomelatine is 2 hours 
and the drug has no active metabolites, any discontinuation 
symptoms would be expected during the first week after 
discontinuation of the active drug. Therefore, the 2-week 
observation period seems to be long enough to rule out any 
emerging withdrawal or discontinuation symptoms. The 
inclusion of only sustained remitters rules out the likeli-
hood of registering reemergent depressive symptoms during 
relapses or partial relapses as discontinuation symptoms. 
Therefore, agomelatine seems to be at lower risk for discon-
tinuation symptoms after abrupt tapering, for example in 
noncompliant patients. This could be an important safety 
benefit during antidepressant therapies.
Patient group/population
Agomelatine has been shown to be effective in the treatment 
of major depression, especially in the subgroup of severely 
depressed patients. In a pooled analysis of placebo-controlled 
studies, agomelatine 25–50 mg was significantly more effec-
tive than placebo.53 Agomelatine also ameliorates sleep-related 
complaints without sedation during the daytime suggesting 
that it may be of special benefit in agitated patients.
No large-scale studies on the long-term effects of 
agomelatine in the treatment of major depression have been 
published so no definite conclusion can be drawn at the 
moment in relation to long-term safety issues or efficacy in 
relapse prevention. Because of this, in 2006 the Committee 
for Medicinal Products for Human Use adopted a negative 
opinion, recommending the refusal of a marketing authori-
sation for the medicinal product Valdoxan/Thymanax® 
(Servier) for the treatment of depression.
However, in a double-blind multicenter study in 
depressed patients the efficacy of agomelatine in relapse 
prevention has been investigated.54 After initial response 
to agomelatine, 492 outpatients continued treatment with 
agomelatine or placebo. During the 6-month study period, 
46.6% of patients receiving placebo, but only 21.7% of 
patients receiving agomelatine, relapsed. Therefore, these 
results indicate that agomelatine might also be effective in 
the long-term treatment of depression.
Place in therapy
Agomelatine is the first melatonergic and 5-HT2C receptor 
antagonistic antidepressant. In all clinical trials published to 
date, including large-scale phase III studies, agomelatine has 
shown at least equal efficacy to active comparators such as 
SSRIs and SNRIs. Furthermore, agomelatine is also effective 
in the treatment of severe depression. In addition, agomela-
tine is the first antidepressant without antihistaminergic side 
effects that effectively ameliorates sleep-related complaints 
without sedation during the daytime.
In all clinical studies the overall tolerability profile of 
agomelatine was excellent and showed no impact on labora-
tory parameters, vital signs, blood pressure, heart rate, and 
QTc time intervals. The rate of treatment-emergent adverse 
events was not higher than with placebo. The sexual accept-
ability of agomelatine represents an important clinical benefit 
as well as the lack of withdrawal symptoms after abrupt 
discontinuation of treatment.
In summary, agomelatine represents a promising novel 
strategy in the treatment of depression. For clinicians it is 
a novel perspective in the acute treatment of depression 
that will hopefully show good clinical effectiveness paired 
with excellent tolerability also in the long-term treatment of 
depressed patients.
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